Joan Sellers
Keine laufenden Positionen mehr
Profil
Joan Sellers was the founder of Vasculogic LLC, which was founded in 1999, where she held the title of Chief Executive Officer in 2006.
She was a Development Director at Targeted Cell Therapies LLC from 2008 to 2010, and a Scientist at Transkaryotic Therapies, Inc. from 1990 to 1994.
She was also the Chief Technology Officer at Boston Therapeutics, Inc. Dr. Sellers earned a doctorate degree from the State University of New York at Albany in 1985.
Ehemalige bekannte Positionen von Joan Sellers
| Unternehmen | Position | Ende |
|---|---|---|
| Targeted Cell Therapies LLC | Corporate Officer/Principal | 01.01.2010 |
| Vasculogic LLC | Gründer | 01.01.2006 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Corporate Officer/Principal | 01.01.1994 |
| NANOMIX CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Joan Sellers
| State University of New York at Albany | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
| Targeted Cell Therapies LLC | |
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
| Vasculogic LLC |
